Advertisement
When should a housing society in Mumbai start considering re...
From GST on JDAs to SEBI’s REIT reclassification and the S...
Stay ahead in the world of real estate with our daily podcas...
Stay ahead in the world of real estate with our daily podcas...
Shukra Pharmaceuticals has secured a letter of intent for 10 acres of land at the Greater Noida Medical Device Park from the Yamuna Expressway Industrial Development Authority to develop an INR 600 crore manufacturing facility. The project will focus on surgical robotics and Boron Neutron Capture Therapy technology for complex cancer treatment. The facility is expected to create significant direct and indirect employment. The company has also partnered with Borns Medical Robotics Inc to establish local manufacturing and distribution of robotic surgery systems in India.
Shukra Pharmaceuticals has received a letter of intent from the Yamuna Expressway Industrial Development Authority for the allotment of 10 acres of land at the Medical Device Park in Greater Noida. The land will be used to set up a manufacturing facility involving an investment of INR 600 crore, marking the company's entry into high-end medical technology manufacturing in the region. Advertisement
The proposed facility will focus on the production of advanced surgical robotics systems and Boron Neutron Capture Therapy technology, a specialised treatment used in managing complex cancer cases. BNCT is still at a limited adoption stage globally and is seen as a niche but growing area within precision oncology, requiring high technical expertise and infrastructure.
According to the company, the project is expected to generate more than 900 direct jobs and around 2,000 indirect employment opportunities once operational. The development is also aligned with the broader objective of strengthening India's domestic medical device manufacturing base, particularly within designated industrial clusters such as the Greater Noida Medical Device Park, which was planned to reduce import dependence in critical healthcare equipment.
Alongside the land allotment, Shukra Pharmaceuticals has entered into a memorandum of understanding with Borns Medical Robotics Inc to introduce surgical robotics technology in India. The collaboration will involve setting up manufacturing and distribution capabilities domestically, with an aim to build a local ecosystem supporting robotic-assisted surgeries.
The company's leadership indicated that the partnership is intended to support self-reliance in medical technology while ensuring that advanced surgical solutions become more accessible and cost-effective for Indian patients. Borns Medical Robotics, which specialises in AI-driven robotic systems, stated that the joint effort would combine its technological expertise with Shukra's market presence to support surgeons and improve consistency in surgical outcomes across India and parts of Asia.
Source PTI
5th Jun, 2025
25th May, 2023
11th May, 2023
27th Apr, 2023
Advertisement
Facebook
Whatsapp
